Interferon-β efficiently inhibited endothelial progenitor cell-induced tumor angiogenesis

Area of Science:

• Oncology
• Gene Therapy
• Vascular Biology

Background:

• Neovascularization is crucial for tumor growth and metastasis.
• Endothelial progenitor cells (EPCs) are recruited to tumors and can promote angiogenesis.
• EPCs offer potential as carriers for targeted cancer therapies.

Purpose of the Study:

• To investigate the role of EPCs in tumor angiogenesis.
• To evaluate the efficacy of genetically modified EPCs as a drug delivery system.
• To assess the anti-tumor effects of human interferon-beta (HuIFN-β) delivered via EPCs.

Main Methods:

• EPCs were genetically modified with HuIFN-β using a viral vector in vitro.
• The anti-cancer activity and bystander effect of HuIFN-β-transduced EPCs were assessed against SPC-A1 cells.
• HuIFN-β-transduced EPCs were co-implanted with SPC-A1 cancer cells in nude mice to evaluate tumor growth and vascular density.

Main Results:

• EPC administration enhanced tumor growth in vivo.
• HuIFN-β-transduced EPCs exhibited potent anti-cancer activity and a bystander effect in vitro.
• IFN-β treatment counteracted the tumor-promoting effects of EPCs, reducing tumor growth, vascular density, and VEGF expression in vivo.

Conclusions:

• Genetically modified EPCs can deliver therapeutic agents like IFN-β to tumor sites.
• Engineered EPCs show promise as a tumor-specific drug delivery system.
• This approach could offer a novel strategy for cancer treatment by combining targeted delivery with therapeutic gene expression.